Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: werewolftx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/3/2024 | $12.00 | Mkt Outperform | JMP Securities |
| 8/24/2023 | $9.00 | Outperform | Wedbush |
| 6/6/2023 | $11.00 → $12.00 | Buy | Jefferies |
| 11/19/2021 | $29.00 → $28.00 | Outperform | SVB Leerink |
| 9/10/2021 | $26.00 | Buy | BofA Securities |
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
3 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
10-Q - Werewolf Therapeutics, Inc. (0001785530) (Filer)
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
S-8 POS - Werewolf Therapeutics, Inc. (0001785530) (Filer)
10-Q - Werewolf Therapeutics, Inc. (0001785530) (Filer)
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)
10-Q - Werewolf Therapeutics, Inc. (0001785530) (Filer)
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 12:55 pm ET on Thursday, December 5, 2024, at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, taking place December 3-5 in Miami, Florida. A
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - - Additional preclinical data demonstrate INDUKINETM molecules' anti-tumor potency with distinct immune activation profiles across four cytokines - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune mediated conditions, today shared
– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting – – Monotherapy and combination expansion arms open and enrolling in ongoing Phase 1/1b clinical trial of WTX-124; initial efficacy data from monotherapy expansion arms anticipated in the first half of 2025 – – Introduced WTX-921, a promising new development candidate and first-of-its kind IL-10 INDUKINE™ molecule for the treatment of inflammatory diseases – – Updated cash guidance provides runway through at least the second quarter of 2026 – WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeu
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced the addition of WTX-921, a novel IL-10 INDUKINE development candidate for Inflammatory Bowel Disease (IBD) and potentially other inflammatory diseases, to the Company's pipeline. This pipeline expansion underscores the transformative promise of the Werewolf's PREDATOR® platform to apply the INDUKINE approach to therapeutic areas outs
WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas. Details for the poster presentations are as follows: Title: INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in Murine Syng
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 11:00 am ET on September 10, 2024, at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. A webcast link for the H.C. Wainwright
– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting – – Encouraging signs of clinical activity at tolerable doses disclosed from ongoing Phase 1 clinical trial of WTX-330 – – Updated data on WTX-124 in combination with pembrolizumab and opening of expansion arms anticipated in the second half of 2024 – – Update on WTX-330 dose escalation and expansion data anticipated at a medical meeting in the fourth quarter of 2024 – WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 - - Early WTX-330 dose-escalation data demonstrated encouraging clinical activity and evidence of immune biomarker activity including an unconfirmed partial response in a metastatic melanoma patient - - Expansion arms open to checkpoint inhibitor-resistant or -naïve relapsed or refractory advanced tumor patients; additional results anticipated in the fourth quarter of 2024 - WATERTOWN, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response - - Monotherapy recommended dose for expansion selected and expansion arms open for enrollment - - Preliminary data on WTX-124 administered to patients in combination with pembrolizumab showed that the combination was generally well-tolerated with enhanced immune activation in tumors - - Company to host webcast to review these data on Monday, June 3, 2024, at 8:00 am ET - WATERTOWN, Mass., June 01, 2024 (
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 1:00 PM ET on June 6 at the Jefferies Global Healthcare Conference, taking place June 4-6, 2024, in New York City, New York. A live webcast link for the Jefferies Global Healthcare Conference
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors. "Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy. I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules," sai
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Meeta Chatterjee, Ph.D., Senior Vice President of Global Business Development at Legend Biotech Corporation, as a member of its board of directors. "I am thrilled to join Werewolf's board of directors as the company prepares to advance investigational new drug applications for its two lead INDUKINETM product candidates, WTX-124 and WTX-330, for the treatment of solid tumors," sai
Veteran life sciences executive brings more than 30 years CMC and product development strategy expertise to rapidly advance programs and oversee manufacturing CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Chulani Karunatilake, Ph.D. as Chief Technology Officer (CTO). Dr. Karunatilake brings more than 30 years of experience in Chemistry and Manufacturing Controls (CMC) process and strategy development and will oversee manufac
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Mike Sherman, chief executive officer of Chimerix, Inc., as a member of its board of directors. "The promise of immunotherapy has long been appreciated, but never fully realized. Werewolf has pioneered an elegant approach that may finally unleash that potential. This platform may translate to multiple drugs to address numerous challenges to treating cancers," Mr. Sherman said. "
HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15 price target.
JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $12 price target.
Ratings for Werewolf Therapeutics (NASDAQ:HOWL) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 2 1 0 0 0 3M Ago 0 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Werewolf Therapeutics, presenting an average target of $13.71, a high estimate of $15.00, and a low estimate of $12.00. Highligh
HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15 price target.
JMP Securities analyst Reni Benjamin reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and maintains $12 price target.
Gainers Structure Therapeutics (NASDAQ:GPCR) stock moved upwards by 71.0% to $58.47 during Monday's regular session. The market value of their outstanding shares is at $2.7 billion. Concord Medical Services (NYSE:CCM) stock rose 55.96% to $0.78. The company's market cap stands at $33.8 million. Microbot Medical (NASDAQ:MBOT) shares moved upwards by 40.79% to $1.41. The market value of their outstanding shares is at $20.2 million. Bio-Path Hldgs (NASDAQ:BPTH) shares moved upwards by 38.0% to $2.84. The market value of their outstanding shares is at $4.7 million. Olema Pharmaceuticals (NASDAQ:OLMA) shares rose 23.45% to $11.95. The market value of their outstanding shares is at $668.4 mil
HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15 price target.
In the latest quarter, 5 analysts provided ratings for Werewolf Therapeutics (NASDAQ:HOWL), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated Werewolf Therapeutics and provided 12-month price targets. The average target is $13.8, accompanied by a high estimate of $15.00 and a low estimate of $12.00. Observing a downward trend, the cu
HC Wainwright & Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and maintains $15 price target.
Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the highest dose tested to date, cohort 4 (12 mg) - Safety data indicate WTX-124 is generally well-tolerated through cohort 4 with no dose limiting toxicities and no indication of vascular leak syndrome (VLS) or other typically severe IL-2-mediated toxicities - Preliminary data support the potential of WTX-124 to be a differentiated next-generation IL-2 compound by showing immune cell activation in the
Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation.Additional posters representing an expansive body of data demonstrating the potential of Werewolf's PREDATOR™ platform and INDUKINE™ product candidates will also be presented.Company to host conference call and webcast to review WTX-124 initial clinical results November 3, 2023, at 8:30 am ET WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the d
JMP Securities initiated coverage of Werewolf Therapeutics with a rating of Mkt Outperform and set a new price target of $12.00
Wedbush initiated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $9.00
Jefferies resumed coverage of Werewolf Therapeutics with a rating of Buy and set a new price target of $12.00 from $11.00 previously
SVB Leerink reiterated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $28.00 from $29.00 previously
BofA Securities initiated coverage of Werewolf Therapeutics with a rating of Buy and set a new price target of $26.00
Evercore ISI Group initiated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $23.00
SVB Leerink initiated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $29.00
Jefferies initiated coverage of Werewolf Therapeutics with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Werewolf Therapeutics with a rating of Buy and set a new price target of $32.00
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13D/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13D/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)
SC 13G - Werewolf Therapeutics, Inc. (0001785530) (Subject)